When we approached him, his view was, 'This is a company with an excellent shot at commercializing cell therapies and that's what I want to do.' So he's completely committed to the cause," CEO Gregg Sando told BioWorld International...Cell Medica is expanding operations after raising $26.5 million in July 2012 in a mixture of public and private funding, including a grant from the Cancer Prevention and Research Institute of Texas, under which it is setting up a manufacturing facility and will run a

Mikael Bronnegard, CEO of Lund, Sweden-based NeuroVive, told BioWorld International that the company has yet to decide whether to take that forward itself or to seek a partner...handed back to Biotica almost two years ago. (See BioWorld International, Aug. 10, 2011.)

Ivan Ahel, group leader at the Paterson Institute for Cancer Research at the University of Manchester in the UK, told BioWorld International: "The question is, can we intentionally inhibit this protein and others that operate in the same pathway

The de-risking of the Biomedical Catalyst grants is attracting new investors," he told BioWorld International

There are certain elements that require protection, mainly related to personal patient data," an EMA spokeswoman told BioWorld International...I don't want to comment on that until the heads of argument are available," AbbVie spokesman Dirk Van Eeden told BioWorld International

handed back to Biotica almost two years ago. (See BioWorld International, Aug. 10, 2011.)

You definitely have to do confirmatory studies to confirm it," Vadsholt told BioWorld International

You definitely have to do confirmatory studies to confirm it," Vadsholt told BioWorld International

We wanted to keep our options open on ALX-0061, and this now allows us to carry on with preparations for the next trial," CEO Edwin Moses told BioWorld International

One of the takeaways from the Avanir experience is that when a partner has a chance to look at the molecules and see that they are differentiated – that they are getting better properties from the deuterated compound than from the non-deuterated agent – that can create a lot of excitement," Tung told BioWorld International

Speaking from the conference, Alastair Kent, director of Genetic Alliance UK, told BioWorld International: "This is good news

Catharina Lavebratt, associate professor in the department of molecular medicine and surgery at the Karolinska Institute in Stockholm, Sweden, told BioWorld International: "We have found a genetic variant that doubles the risk of developing psychotic features among people with bipolar disorder

Roth Capital Partners was the placement agent 2/13/13 Notes: Currency conversions are based on exchange rates at the time of the deal. ** Denotes the date the item ran in BioWorld International

I think it's not totally unreasonable," Richard Parkes, analyst at Deutsche Bank in London, told BioWorld International...The question is what do we think peak revenues for Tysabri can be," Nick Turner, analyst at Mirabaud Securities in London, told BioWorld International

When added to £350,000 in nondilutive grant funding received to date, that will allow the London-based company to shape up the technology, develop the business plan and move to raising a Series A of up to £12 million, CEO Davidson Ateh told BioWorld International

Raùl Méndez, group leader at the Institute for Research in Biomedicine in Barcelona, told BioWorld International: "We have found the mechanism that tumors use to reactivate the properties of the embryo

We have upped the credibility of those sites within the corporate structure," Mary Shire, UL's vice president of research, told BioWorld International...It's an area that has been "underserved and underresearched" until now, Kenny told BioWorld International

We need to wait and see what the EMA is going to say," Salvatore Calabrese, Gentium's chief financial officer, told BioWorld International

I think it's not totally unreasonable," Richard Parkes, analyst at Deutsche Bank in London, told BioWorld International...The question is what do we think peak revenues for Tysabri can be," Nick Turner, analyst at Mirabaud Securities in London, told BioWorld International